DENALI THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF AVLAYAH™ (TIVIDENOFUSP ALFA-EKNM) FOR TREATMENT OF HUNTER SYNDROME (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage transferrin receptor to cross blood-brain barrier Denali’s first medicine enabled by its TransportVehicle™ platform designed to deliver biotherapeutics to whole body, including brain Rare Pediatric Disease […]

Read More

Stakeholder Feature: Recursion

Recursion is a Salt Lake City–based company using AI and scientific innovation to discover and develop new medicines for people living with diseases that often have few or no treatment options, including rare diseases. Around the world, an estimated 300 million people are affected by a rare disease, yet only about 5% of rare diseases […]

Read More

Courageous Hope: Action Before Answers

By: Stacy Allen Most people think of hope as something passive, a feeling you hold onto while waiting for things to improve. But real hope, the kind that changes outcomes, looks very different. It’s active. It’s uncomfortable. And often, it shows up before there are any answers at all. That’s what I’ve come to understand […]

Read More